TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

Size: px
Start display at page:

Download "TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS"

Transcription

1 TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

2 THE DOORS ARE OPEN: FEEL FREE TO COME IN

3 CENTOGENE UNLOCKS THE POWER OF GENETIC INSIGHTS TO IMPROVE THE QUALITY OF LIFE OF PATIENTS WITH GENETIC DISEASES. We achieve this through: Knowledge created by our worldwide diagnostic testing services incorporating unprecedented global diversity The world s leading, proprietary human genetic interpretation database, CentoMD Solutions for pharmaceutical companies developing life-changing orphan drugs Maintaining the highest levels of accreditation to assure the best quality in our processes We are dedicated to transforming the science of genetic information into solutions and hope for patients and their families.

4 HOW CENTOGENE WORKS Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners. Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient. Our work does not end with the identification of the genetic mutation behind a particular disorder. We continuously improve our services. Over 60 medical experts, human geneticists and researchers work together with partners worldwide. 4

5 ALL OVER THE WORLD PHYSICIANS AND PATIENTS VALUE OUR EXPERTISE IN HUMAN GENETIC TESTING STRATEGIC PHARMACEUTICAL ALLIANCES IN THE ORPHAN DRUGS SECTOR DIAGNOSTIC INDUSTRY KNOWLEDGE DRIVEN PRODUCTS ➋ Offering worldwide innovative genetic testing service. Developing comprehensive databases and a unique Creating new solutions for pharmaceutical companies (screening programs, companion diagnostics, early identification programs). Developing of unique IP, focusing on big data for the early diagnosis and long term monitoring of patients. biobank of patients material. 5

6 Statistics PROVEN BY NUMBERS Have a look behind the scenes. Not all of a company s value can be discovered at first sight. Convincing numbers are found everywhere that underline CENTOGENE s leading position as a globally acting biotech company. 6

7 5 AFFILIATES GLOBAL 13 DIFFERENT TECHNOLOGICAL PLATFORMS EMPLOYEES FROM 42 COUNTRIES SAMPLES FROM MORE THAN ,200 COUNTRIES WORLDWIDE EMPLOYEES CONFIRMED CASES OF FABRY DISEASE 40, SAMPLES PROCESSED IN JANUARY-JUNE 2017 MILLION UNIQUE GENETIC VARIANTS RATED IN CentoMD MILLION ALLELES IDENTIFIED 7

8 OUR GLOBAL FOOTPRINT One accompaniment of growth and expansion at CENTOGENE is the inauguration of new affiliates. As a cosmopolitical company we have a strong international footprint. 8

9 GROWN UP IN JUST A FEW YEARS Protein biomarkers MLPA >180 NGS panels Oncogenetics 2006 Diagnostics in neurogenetic diseases CentoCard The logistic solution qpcr Whole exome sequencing Whole genome sequencing Microarrays Non-invasive prenatal testing Transcriptomics CentoMD The mutation database High throughput genomic facility Pharmacogenomics 9

10 GENETIC TESTING: EFFICIENT, RELIABLE AND REASONABLE CentoCard Dried blood spot (DBS) filtercards for patient sample collection and shipment. The simplest way to ship biological samples as easy as mailing a postcard making genetic testing available anywhere in the world. 2h 10

11 CentoCard IN DETAIL: CentoCard is easy to handle: samples are stable once they dry and can be mailed directly by regular post Samples collected on CentoCard are not sensitive over time or to temperature, nor are they considered biohazardous CentoCard is usable for every analysis and testing method, including whole exome and whole genome sequencing CentoPortal Your solution for smarter diagnostics. CentoPortal is the user-friendly, online ordering and tracking portal designed to assist you at every step of processing your patients samples. From online ordering and sample submission through to receipt of the final clinical diagnostic report, CentoPortal is designed to save time and reduce overall workload. CentoPortal 11

12 TGA GAT ACT CGA TCG TCA GCT AAG TAG CCG CentoMD CentoMD is the world s largest mutation database for rare diseases. This virtual encyclopedia of genetic, clinical and epidemiological information is based on analyzed and fully curated samples from over 115 countries. It enables you to increase your diagnostic know-how and cross-reference multiple ethnic backgrounds with gender/age-specific clinical symptoms. CentoMD 4.0 is going to transform the future of genetics. Revealing the cause of a disease has an immediate impact on the patient. Using all available information allows physicians to diagnose and treat hereditary diseases in a much more efficient, speedy and targeted manner. 12

13 58% 42% > 135,000 Analysed cases > 3,200 Associated phenotypes 58% CentoMD 42% published Ratio of newly detected vs. previously published clinically relevant and uncertain variants > 925 Million Identified alleles > 4,5 Million Unique variants CentoMD is evidence-based. Behind every reported variant there is a clinical case analyzed at CENTOGENE by following a highly standardized workflow with accredited quality. CentoMD 4.0 is your simple six-step solution. Search, select and filter through genes, transcripts, and variants and end up with a detailed description including all associated data tailored to your needs. With CentoMD, you now have a virtual encyclopedia of genetic information, allowing you to diagnose and treat rare diseases in a much more efficient, speedy and targeted manner. 13

14 CentoXome For certain patients the combination of symptoms does not allow the clinician to pinpoint a potential diagnosis. Therefore, ordering genetic testing becomes complex and might involve a stepwise diagnostic strategy, which often significantly increases costs. Furthermore, a delayed diagnosis may have a dramatic impact on the patient s quality of life. KEY BENEFITS OF WHOLE EXOME SEQUENCING (WES) A cost-effective, one-step solution by sequencing the entire protein coding region of an individual s DNA (includes about 85% of all known disease causing mutations) WHEN IS WES RECOMMENDED? WES is especially recommended for patients with: Heterogeneous phenotypes Complex and unclear phenotypes CentoXome - HIGHEST QUALITY STANDARDS About 97-98% of coding regions are covered reliably Includes validation of the sequencing results and an extended clinical report 14

15 CentoGenome A comprehensive view of patients genetic data. Existing research and diagnosis of especially rare genetic diseases have been heavily biased towards mutations in coding regions of the gene - but this covers only 1% of a patient s entire genome. WGS identifies any changes in a patient s DNA by sequencing the entire coding and non-coding regions of the genome. It provides detailed information on the thousands of genes involved in normal growth and development and all of the silent genome regions simultaneously. CentoGenome brings conclusive diagnostic answers in the fastest, most reliable way: HETEROGENEOUS GENETIC DISORDER CONVENTIONAL GENETIC TESTING (Single gene sequencing, gene panel sequencing, CNVs testing, exome sequencing ) $ $ $ CentoGenome 28% DIAGNOSTIC REPORT? No answers? Answers! TEST METHOD DESCRIPTION LIKELIHOOD OF DETECTING A SPECIFIC MUTATION* INFORMATION CONTENT WHOLE EXOME SEQUENCING ANALYZES THE CODING PART OF THOUSANDS OF GENES SIMULTANEOUSLY >93.2% ~60 MB WHOLE GENOME SEQUENCING ANALYZES THE WHOLE GENOME >97.6% ~3.2 GB *within the targeted region 15

16 EARLY DETECTION MONITORING TREATMENT EFFECTIVENESS DISEASE RISK ASSESSMENT DIAGNOSTIC CLASSIFICATION FOR TREATMENT INITIATION Biomarker Enabling diagnosis, prediction and therapy monitoring. CENTOGENE s biomarkers Easy to be analyzed using DBS (dried blood spots) technology Linked to clinical manifestation Quantify easily and reliably in clinical samples Reflect realistically the burden of the disease Elucidate the molecular pathogenesis of the disease Reflect the therapeutic measure outcomes Novel mass-spectrometry (MS) based biomarkers for LSDs Proven world-class expertise in the identification of new biomarkers, validated in epidemiological clinical trials Established MS-based proprietary biomarker tests for Gaucher, Niemann-Pick type A/B and C, Fabry, Farber and Cystic Fibrosis Optimized and facilitated sample logistics with our CE labeled filtercards, CentoCard 16

17 BLOOD PLASMA DBS m/z ANALYTICAL VALIDATION Mass spectrometry CLINICAL VALIDATION Healthy controls, carriers, affected patients CLINICAL APPLICATION Prognosis, diagnosis, therapy GAUCHER DISEASE NIEMANN PICK TYPE A/B AND C DISEASE Examples FABRY DISEASE FARBER DISEASE CYSTIC FIBROSIS Benefits of CENTOGENE s biomarkers Analytical superiority Simplified logistics and analysis in blood, plasma, and DBS (CentoCard ) High sensitivity and specificity Clinical superiority Shortest TAT Interpretation by scientific and medical experts For more details: 17

18 CentoAcademy CentoAcademy is CENTOGENE s educational workshop series. Via lecture, seminar and hands-on multi-day courses, clinical scientists and physicians all over the world are given the opportunity to learn about: Cutting-edge diagnostic technologies Global best practices Research innovations Services Sharing our knowledge with our partners in personal seminars and workshops is the best basis for a good understanding of complex technological workflows. 18

19 CentoWebinar Wherever you are, connect with us live, or whenever it suits you, listen to topics of your interest in clinical diagnostics practice and research. At CENTOGENE, we established a free webinars series (live and on demand) on key developments in clinical diagnostics as well as giving insights into the latest research findings in the field of rare disease. Benefit from our renowned speakers and let us support you with daily routine implementation. 19

20 ACTIONS SPEAK LOUDER THAN WORDS CENTOGENE S SOCIAL RESPONSIBILITY CENTOGENE recognizes its social obligation and is undertaking active and initiates or supports projects for an early engagement and integrated communication with all people dealing with rare diseases. 20

21

22 WE ANSWER ALL YOUR QUESTIONS We are continuously improving our services to meet the needs of our partners. Please do not hesitate to send us your inquiry, your feedback or your comments. We guarantee a reply to your inquiry within 24 hours maximum. All information are confidential and not transferable to a third party. We want to thank you for your time and most importantly your feedback. dmqc@centogene.com +49 (0)

23

24 PLEASE VISIT OUR WEBSITE FOR MORE INFORMATION: CONTACT DETAILS: CENTOGENE AG Doreen Niemann Schillingallee Rostock Germany +49 (0) (0) CLIA #99D V2eng_August2017

Genomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC

Genomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC Genomic Research: Issues to Consider IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC Outline Key genomic terms and concepts Issues in genomic research Consent models Types of findings Returning results

More information

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego

Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Discuss the difference between DNA Genotyping and Genome Sequencing What makes you who you

More information

Comments on Use of Databases for Establishing the Clinical Relevance of Human Genetic Variants

Comments on Use of Databases for Establishing the Clinical Relevance of Human Genetic Variants Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 The American Society of Human Genetics 9650 Rockville Pike Bethesda, MD 20814 24 December

More information

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise

More information

Human Genome. The Saudi. Program. An oasis in the desert of Arab medicine is providing clues to genetic disease. By the Saudi Genome Project Team

Human Genome. The Saudi. Program. An oasis in the desert of Arab medicine is providing clues to genetic disease. By the Saudi Genome Project Team By the Saudi Genome Project Team The Saudi image licensed by ingram publishing Human Genome Program An oasis in the desert of Arab medicine is providing clues to genetic disease. Digital Object Identifier

More information

Mutation entries in SMA databases Guidelines for national curators

Mutation entries in SMA databases Guidelines for national curators 1 Mutation entries in SMA databases Guidelines for national curators GENERAL CONSIDERATIONS Role of the curator(s) of a national database Molecular data can be collected by many different ways. There are

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Next Generation Sequencing. Target Enrichment

Next Generation Sequencing. Target Enrichment Next Generation Sequencing Target Enrichment Next Generation Sequencing Your Partner in Every Step from Sample to Data NGS: Revolutionizing Genetic Analysis with Single-Molecule Resolution Next generation

More information

NHS ENGLAND BOARD PAPER

NHS ENGLAND BOARD PAPER NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce

More information

Disease Specific Registries vs Product Registries

Disease Specific Registries vs Product Registries 1 Disease Specific Registries vs Product Registries Professor Hanns Lochmüller Newcastle University 2 What is TREAT-NMD? A network of excellence funded by the European Union (but with global collaborations)

More information

UNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process

UNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process Genetic discovery AHC Patients Need Help! Researchers collect data on AHC patients (observation) Researchers interpret and evaluate data AHC

More information

Molecule-specific diagnosis of metabolic diseases

Molecule-specific diagnosis of metabolic diseases Powered by Website address: https://www.gesundheitsindustriebw.de/en/article/news/molecule-specific-diagnosis-ofmetabolic-diseases/ Molecule-specific diagnosis of metabolic diseases Lysosomal storage diseases

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing

More information

Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare

Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly

More information

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)

GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS

More information

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association

Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory

More information

Personalized. Health in Canada

Personalized. Health in Canada Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute

More information

ORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet

ORPHANET s Services for Researchers. Valérie THIBAUDEAU Database Manager Orphanet ORPHANET s Services for Researchers Valérie THIBAUDEAU Database Manager Orphanet Services for Researchers Needs Access classifications, genes Identify experts Collaborate Quickly recruit volunteers Establish

More information

Handbook. Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1

Handbook. Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1 Handbook Precautions/warnings: For professional use only. To support clinical diagnosis. Not yet offered in the US. Page 1 CentoMDx TM 1.1_Handbook_V1.1_March2018 Contents Introduction... 3 Intended use...

More information

Ion S5 and Ion S5 XL Systems

Ion S5 and Ion S5 XL Systems Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Explore the Ion S5 and Ion S5 XL Systems Adopting next-generation sequencing (NGS) in your lab is now simpler than ever The Ion S5

More information

Exam MOL3007 Functional Genomics

Exam MOL3007 Functional Genomics Faculty of Medicine Department of Cancer Research and Molecular Medicine Exam MOL3007 Functional Genomics Tuesday May 29 th 9.00-13.00 ECTS credits: 7.5 Number of pages (included front-page): 5 Supporting

More information

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report

More information

Welcome to the NGS webinar series

Welcome to the NGS webinar series Welcome to the NGS webinar series Webinar 1 NGS: Introduction to technology, and applications NGS Technology Webinar 2 Targeted NGS for Cancer Research NGS in cancer Webinar 3 NGS: Data analysis for genetic

More information

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics

More information

Genomic Data Is Going Google. Ask Bigger Biological Questions

Genomic Data Is Going Google. Ask Bigger Biological Questions Genomic Data Is Going Google Ask Bigger Biological Questions You know your research could have a significant scientific impact and answer questions that may redefine how a disease is diagnosed or treated.

More information

Konica Minolta to Acquire Ambry Genetics (US)

Konica Minolta to Acquire Ambry Genetics (US) Konica Minolta to Acquire Ambry Genetics (US) Full-fledged Entry into Precision Medicine July 6, 2017 0 1. Transaction Details and Positioning in KM s Strategy 2. Full-fledged Entry into Precision Medicine

More information

Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy?

Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy? Regulatory Challenges and Threats in Orphan Drug Development Are Ultra Orphans Easy? EPLS September 24, 2014 Ulrich Granzer Granzer Regulatory Consulting & Services The Challenge: What needs to be done

More information

PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14

PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 PHYSICIAN RESOURCES MAPPED TO GENOMICS COMPETENCIES AND GAPS IDENTIFIED WITH CURRENT EDUCATIONAL RESOURCES AVAILABLE 06/04/14 Submitted resources from physician organization representatives were mapped

More information

QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd

QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd 1 Our current NGS & Bioinformatics Platform 2 Our NGS workflow and applications 3 QIAGEN s

More information

Proteomics And Cancer Biomarker Discovery. Dr. Zahid Khan Institute of chemical Sciences (ICS) University of Peshawar. Overview. Cancer.

Proteomics And Cancer Biomarker Discovery. Dr. Zahid Khan Institute of chemical Sciences (ICS) University of Peshawar. Overview. Cancer. Proteomics And Cancer Biomarker Discovery Dr. Zahid Khan Institute of chemical Sciences (ICS) University of Peshawar Overview Proteomics Cancer Aims Tools Data Base search Challenges Summary 1 Overview

More information

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry

Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Lecture 23: Clinical and Biomedical Applications of Proteomics; Proteomics Industry Clinical proteomics is the application of proteomic approach to the field of medicine. Proteome of an organism changes

More information

Target Enrichment Strategies for Next Generation Sequencing

Target Enrichment Strategies for Next Generation Sequencing Target Enrichment Strategies for Next Generation Sequencing Anuj Gupta, PhD Agilent Technologies, New Delhi Genotypic Conference, Sept 2014 NGS Timeline Information burst Nearly 30,000 human genomes sequenced

More information

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D. Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food

More information

Genomic Medicine in France

Genomic Medicine in France Genomic Medicine in France Catherine Nguyen, PhD Director ITMO GGB Genetic, Genomic & Bioinformatic Advancing Disease Modeling in Animal-Based research in Support of Precision Medecine: a Workshop ILAR

More information

Utilizing Innovative Statistical Methods. Discussion Guide

Utilizing Innovative Statistical Methods. Discussion Guide Utilizing Innovative Statistical Methods and Trial Designs in Rare Disease Settings Discussion Guide Background Rare diseases are a complex and diverse set of conditions which, when taken together, affect

More information

Bridging the Gap in Precision Medicine An Informatics Solution Connecting Research, Pathology, and Clinical Care

Bridging the Gap in Precision Medicine An Informatics Solution Connecting Research, Pathology, and Clinical Care Bridging the Gap in Precision Medicine An Informatics Solution Connecting Research, Pathology, and Clinical Care O R A C L E W H I T E P A P E R F E B R U A R Y 2 0 1 6 Disclaimer The following is intended

More information

Meeting report series

Meeting report series Meeting report series Report of the 2 nd DSC Working Group on Model Systems teleconference December 16, 2013 Organization Organized by: IRDiRC Scientific Secretariat Teleconference Participants Prof Phil

More information

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient

More information

MOSAIQUES DIAGNOSTICS

MOSAIQUES DIAGNOSTICS MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development

More information

Integrating Genomics in Family Medicine

Integrating Genomics in Family Medicine Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and

More information

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters

More information

Reporting Results and Incidental Findings to Research Participants

Reporting Results and Incidental Findings to Research Participants Reporting Results and Incidental Findings to Research Participants Jeffrey R Botkin, MD, MPH Professor of Pediatrics Chief, Division of Medical Ethics and Humanities Associate Vice President for Research

More information

Ion S5 and Ion S5 XL Systems

Ion S5 and Ion S5 XL Systems Ion S5 and Ion S5 XL Systems Targeted sequencing has never been simpler Introducing the Ion S5 and Ion S5 XL systems Now, adopting next-generation sequencing in your lab is simpler than ever. The Ion S5

More information

E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research

E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution

More information

WHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs

WHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs 1 Executive Summary In today s complex healthcare landscape, the success or failure of a new therapeutic intervention depends

More information

Leveraging an Academic-Industry Partnership for Commercial Success

Leveraging an Academic-Industry Partnership for Commercial Success Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,

More information

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development

More information

CRO partner in Rx/CDx Co-Development

CRO partner in Rx/CDx Co-Development CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics

More information

Complete automation for NGS interpretation and reporting with evidence-based clinical decision support

Complete automation for NGS interpretation and reporting with evidence-based clinical decision support Brochure Bioinformatics for Clinical Oncology Testing Complete automation for NGS interpretation and reporting with evidence-based clinical decision support Sample to Insight Powering clinical insights

More information

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International

More information

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary

More information

Opportunities for industry/smes in EU-funded health research

Opportunities for industry/smes in EU-funded health research Opportunities for industry/smes in EU-funded health research Stéphane Hogan, M.Sc, MBA Head of Unit Applied Genomics and Biotechnology for Health DG Research - European Commission 1 Paris, 31 May 2005

More information

Rare Diseases: Challenges and Opportunities NIH Perspective

Rare Diseases: Challenges and Opportunities NIH Perspective Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes

More information

Learning Objectives. Introduction

Learning Objectives. Introduction Tools for Teaching Genetics in Primary Care Charles J. Macri, MD Leon Moore, Ph.D. NEGEA Baltimore, Maryland 3 March 2001 Learning Objectives Why is genetics an important topic for discussion now? Identify

More information

Roche, Roche Molecular Diagnostics and more

Roche, Roche Molecular Diagnostics and more , Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional

More information

Healthcare Supply Chain Solutions

Healthcare Supply Chain Solutions Healthcare Supply Chain Solutions Managed Logistics Cold Chain Logistics Express Delivery to over 220 Countries Worldwide D E L I V E R P L U S D E L I V E R S M O R E! Deliver Plus provides premium managed

More information

Stability Testing for Pre-Clinical and Early Phase Clinical Drug Products

Stability Testing for Pre-Clinical and Early Phase Clinical Drug Products Microrite, Inc. brings you this unique learning experience in Stability Testing for Pre-Clinical and Early Phase Clinical Drug Products; Part of Microrite s step-by-step webinar series. Stability Testing

More information

Clinical Genomics and NGS Bertinoro (Italy), April 29 May 4, st Course jointly organized by ESGM, ESHG AND CEUB

Clinical Genomics and NGS Bertinoro (Italy), April 29 May 4, st Course jointly organized by ESGM, ESHG AND CEUB Clinical Genomics and NGS Bertinoro (Italy), April 29 May 4, 2018 31 st Course jointly organized by ESGM, ESHG AND CEUB Target Audience: This course is for those young professionals in Clinical and Medical

More information

Examples of founding and evolving leading LifeScience companies. November 2016

Examples of founding and evolving leading LifeScience companies. November 2016 Examples of founding and evolving leading LifeScience companies November 2016 Peter Pohl Born: in Salzburg Love: my wife and my two children (age 9&7) Education: Business Adminstration Serial entrepreneur

More information

State of the Art in Data Management for Precision Medicine & Genomics. March 8, pm 3 pm ET

State of the Art in Data Management for Precision Medicine & Genomics. March 8, pm 3 pm ET State of the Art in Data Management for Precision Medicine & Genomics March 8, 2017 2 pm 3 pm ET Housekeeping Issues All participants are muted To ask a question or make a comment, please submit via the

More information

Implementing an e-validation Solution at Myriad Genetics

Implementing an e-validation Solution at Myriad Genetics Implementing an e-validation Solution at Myriad Genetics 1 Slide Index Company Background Business Drivers for an e-validation Solution Alternatives Considered Key requirements Assessment Implementation

More information

CHARTING THE COURSE FOR PRECISION MEDICINE

CHARTING THE COURSE FOR PRECISION MEDICINE A Friends of Cancer Research White Paper CHARTING THE COURSE FOR PRECISION MEDICINE ADOPTING CONSENSUS ANALYTICAL STANDARDS AND STREAMLINING APPROVAL PATHWAYS FOR POST-MARKET MODIFICATIONS FOR NGS TESTS

More information

Biomedical Big Data and Precision Medicine

Biomedical Big Data and Precision Medicine Biomedical Big Data and Precision Medicine Jie Yang Department of Mathematics, Statistics, and Computer Science University of Illinois at Chicago October 8, 2015 1 Explosion of Biomedical Data 2 Types

More information

The In Vitro Diagnostic CRO

The In Vitro Diagnostic CRO The In Vitro Diagnostic CRO Choose Beaufort Because of Our People, Processes and Proven Experience The value of expertise cannot be overstated, especially when it comes to streamlining complicated in vitro

More information

UK Biobank Axiom Array

UK Biobank Axiom Array DATA SHEET Advancing human health studies with powerful genotyping technology Array highlights The Applied Biosystems UK Biobank Axiom Array is a powerful array for translational research. Designed using

More information

Integrating Pharmacogenomics into Decision Making

Integrating Pharmacogenomics into Decision Making Integrating Pharmacogenomics into Decision Making Munir Pirmohamed David Weatherall Chair of Medicine and NHS Chair of Pharmacogenetics Department of Molecular and Clinical Pharmacology Institute of Translational

More information

Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA

Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA Integrated Radiology & Pathology Diagnostic Services: The Time is Now at UCLA Scott W Binder MD Pritzker Professor of Clinical Pathology and Dermatology Senior Vice Chair Director, Pathology Clinical Services

More information

Lecture #1. Introduction to microarray technology

Lecture #1. Introduction to microarray technology Lecture #1 Introduction to microarray technology Outline General purpose Microarray assay concept Basic microarray experimental process cdna/two channel arrays Oligonucleotide arrays Exon arrays Comparing

More information

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Specify countries: Name of person previously tested and relationship:

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Specify countries: Name of person previously tested and relationship: REQUEST FOR SITE SPECIFIC ANALYSIS [APC / MYH / TP53 / MLH1 / MSH2 / MSH6] Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS

More information

Gene Expression Analysis Superior Solutions for any Project

Gene Expression Analysis Superior Solutions for any Project Gene Expression Analysis Superior Solutions for any Project Find Your Perfect Match ArrayXS Global Array-to-Go Focussed Comprehensive: detect the whole transcriptome reliably Certified: discover exceptional

More information

Targeted Sequencing in the NBS Laboratory

Targeted Sequencing in the NBS Laboratory Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February

More information

Personal Genomics Platform White Paper Last Updated November 15, Executive Summary

Personal Genomics Platform White Paper Last Updated November 15, Executive Summary Executive Summary Helix is a personal genomics platform company with a simple but powerful mission: to empower every person to improve their life through DNA. Our platform includes saliva sample collection,

More information

+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA

+ + + MALARIA HIV/AIDS TUBERCULOSIS LEISHMANIASIS CHAGAS DISEASE DENGUE EBOLA ZIKA At the Center for Infectious Disease Research, we use systems biology approaches and cutting-edge technologies to accelerate the development of life-saving drugs, diagnostics and treatments for the world

More information

ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES

ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES ALLERGAN ENTERS STRATEGIC R&D ALLIANCE WITH EDITAS MEDICINE TO DISCOVER AND DEVELOP CRISPR GENE EDITING PROGRAMS FOR OCULAR DISEASES Novel Development Programs for Potential Treatments of Serious Ocular

More information

TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY

TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY 1. Patient Information Patient Name TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY HudsonAlpha Clinical Services Lab, LLC HUDSONALPHA CLINICAL SERVICES LABORATORY

More information

ACCELERATING GENOMIC ANALYSIS ON THE CLOUD. Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes

ACCELERATING GENOMIC ANALYSIS ON THE CLOUD. Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes ACCELERATING GENOMIC ANALYSIS ON THE CLOUD Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia to analyze thousands of genomes Enabling the PanCancer Analysis of Whole Genomes (PCAWG) consortia

More information

Fundamentals of Clinical Genomics

Fundamentals of Clinical Genomics Fundamentals of Clinical Genomics Wellcome Genome Campus Hinxton, Cambridge, UK 17-19 January 2018 Lectures and Workshops to be held in the Rosalind Franklin Pavilion Lunch and Dinner to be held in the

More information

Next Generation Sequencing (NGS) Market Size, Growth and Trends ( )

Next Generation Sequencing (NGS) Market Size, Growth and Trends ( ) Next Generation Sequencing (NGS) Market Size, Growth and Trends (2014-2020) July, 2017 4 th edition Information contained in this market report is believed to be reliable at the time of publication. DeciBio

More information

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. P70.4 Neonatal hypoglycemia Q79.59 Omphalocele P08.1 Large for gestational age

FIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. P70.4 Neonatal hypoglycemia Q79.59 Omphalocele P08.1 Large for gestational age REQUEST FOR BECKWITH-WIEDEMANN SYNDROME (BWS) TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION*

More information

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT

More information

Standards of proficiency. Biomedical scientists

Standards of proficiency. Biomedical scientists Standards of proficiency Biomedical scientists Contents Foreword 1 Introduction 3 Standards of proficiency 7 Foreword We are pleased to present the Health and Care Professions Council s standards of proficiency

More information

Expression Array System

Expression Array System Integrated Science for Gene Expression Applied Biosystems Expression Array System Expression Array System SEE MORE GENES The most complete, most sensitive system for whole genome expression analysis. The

More information

Corporate Medical Policy Genetic Testing for Fanconi Anemia

Corporate Medical Policy Genetic Testing for Fanconi Anemia Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2017 3/2018 12/2017 Description

More information

An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case

An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case Bench Lab CASE STUDY An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case Authors: Matthew J. McGinniss 1, PhD FACMG, Executive Director, Molecular

More information

The Intersection of Genomics Research and the IDE Regulation

The Intersection of Genomics Research and the IDE Regulation The Intersection of Genomics Research and the IDE Regulation Katherine Donigan, Ph.D. Personalized Medicine Staff FDA/CDRH/OIR October 19, 2017 1 In Vitro Diagnostic (IVD) Regulation Through the 1976 medical

More information

A BioPontis Alliance Report. Integrating Rare Disease Patients into Pre-Clinical Therapy Development; Finding our Way with Patient Input

A BioPontis Alliance Report. Integrating Rare Disease Patients into Pre-Clinical Therapy Development; Finding our Way with Patient Input A BioPontis Alliance Report Integrating Rare Disease Patients into Pre-Clinical Therapy Development; Finding our Way with Patient Input December 2016 Integrating Rare Disease Patients into Pre-Clinical

More information

Personalized Medicine

Personalized Medicine Personalized Medicine Dr. Pablo Mentzinis, Director Government Relations, SAP SE Courtesy by Dominik Bertram, Marc von der Linden, Péter Adorján, SAP June 2016 1. Traditional medicine vs. personalized

More information

article Genetics IN Medicine 337

article Genetics IN Medicine 337 May 2008 Vol. 10 No. 5 article Molecular testing: improving patient care through partnering with laboratory genetic counselors Cheryl Scacheri, MS 1, Joy B. Redman, MS 2, Lisa Pike-Buchanan, ScM 3, and

More information

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3 European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE

More information

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS William S. Dalton, PhD, MD CEO, M2Gen & Director, Personalized Medicine Institute, Moffitt Cancer Center JULY 15, 2013 MOFFITT CANCER CENTER

More information

The Pathways to Understanding Diseases

The Pathways to Understanding Diseases FOR PHARMA & LIFE SCIENCES White paper The Pathways to Understanding Diseases Deciphering complex biological processes Executive Summary Understanding complex biological processes is critical whether doing

More information

QuantStudio Dx Real-Time PCR Instrument

QuantStudio Dx Real-Time PCR Instrument QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help

More information

CAMAG. Jack Henion, Emeritus Professor Cornell University and VP of R&D. at Quintiles Bioanalytical and ADME Labs, USA

CAMAG. Jack Henion, Emeritus Professor Cornell University and VP of R&D. at Quintiles Bioanalytical and ADME Labs, USA CAMAG DBS-MS 500 ONLINE EXTRACTION SYSTEM FOR LC-MS, MS OR auto COLLECTOR COUPLING The DBS-MS 500 handles the unattended analysis of up to 2000 DBS samples which is particularly beneficial when very large

More information

Gen e e n t e i t c c V a V ri r abi b li l ty Biolo l gy g Lec e tur u e e 9 : 9 Gen e et e ic I n I her e itan a ce

Gen e e n t e i t c c V a V ri r abi b li l ty Biolo l gy g Lec e tur u e e 9 : 9 Gen e et e ic I n I her e itan a ce Genetic Variability Biology 102 Lecture 9: Genetic Inheritance Asexual reproduction = daughter cells genetically identical to parent (clones) Sexual reproduction = offspring are genetic hybrids Tendency

More information

ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research

ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research ISPOR 19 th International Meeting May 31 st June 4 th 2014, Montréal International Society for Pharmacoeconomics and Outcomes Research Pascale Boyer Barresi, CFA Business Analysis, BD&L September 2014

More information

Towards unbiased biomarker discovery

Towards unbiased biomarker discovery Towards unbiased biomarker discovery High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised

More information

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome

More information